Lascco SA is a biomedical-technology development private company based at the Biopole of Lausanne, Switzerland.

The primary objective of LASCCO is to bring promising early-stage biomedical technologies – therapeutics and diagnostics – developed in research institutes to the attention of the pharmaceutical industry.
The company’ portfolio is currently composed of two critical care products based on innovative technologies and aiming at fighting sepsis and treating severe bacterial and viral infections.